FDA mulls behind-the-counter drug category

Share this article:

The FDA said it may create a new “behind-the-counter” (BTC) category of drugs made available at drugstores to patients without a prescription, but only after consultation with a pharmacist.

The agency will hold a public meeting to hear feedback about on the BTC concept on Nov. 14. The purpose of the meeting is to solicit information and views on specific issues associated with BTC availability.
 
There are currently only a few drugs available BTC in the US – one is Barr's Plan B birth control drug.

However, countries such as Australia, Canada and New Zealand use the BTC system more widely.

According to the FDA, the criteria generally used BTC status in other countries include suitability for self-diagnosis and a low potential for serious side effects and overdose.

“Because pharmacists have the training and knowledge to provide certain interventions, they may be able to ensure that patients meet the conditions for use and educate patients on appropriate use of the drug product,” the FDA said in a Federal Register notice.

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

More in News

Five things for Pharma Marketers to Know: Thursday, August 28

Five things for Pharma Marketers to Know: Thursday, ...

Human testing of GSK's Ebola virus starts next week, menopause is a costly healthcare concern, and a small conversation with pharmacists may have a big impact.

Judge blocks FDA bid to allow generic Precedex

Judge blocks FDA bid to allow generic Precedex

The US District Court for Maryland granted Hospira a temporary restraining order (TRO) against FDA, after the agency determined that potential generic competitors of the company's injectable sedation drug Precedex ...

GSK drug gets aplastic anemia indication

GSK drug gets aplastic anemia indication

Promacta was previously indicated for chronic immune thrombocytopenia.